Oncology nursing in a new era: optimizing treatment with bevacizumab

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Vascular Endothelial Growth Factor (VEGF) overexpression drives tumor angiogenesis and progression.
• Bevacizumab targets VEGF, inhibiting tumor growth and enhancing chemotherapy efficacy.
• VEGF inhibition is crucial in managing various metastatic cancers.

Purpose of the Study:

• To review the role of bevacizumab in treating metastatic colorectal cancer, non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC).
• To outline strategies for patient selection, treatment duration, and side effect management.
• To support oncology nurses in patient education and adherence to bevacizumab therapy.

Main Methods:

• Literature review on bevacizumab's mechanism of action, clinical efficacy, and safety profile.
• Analysis of clinical trial data for metastatic colorectal cancer, NSCLC, and mBC.
• Discussion of nursing implications for managing bevacizumab therapy and its toxicities.

Main Results:

• Bevacizumab combined with chemotherapy improves progression-free and overall survival in specific metastatic cancers.
• Key side effects include hypertension, proteinuria, bleeding, and thrombotic events.
• Effective management of side effects is critical for patient safety and treatment adherence.

Conclusions:

• Bevacizumab is an effective anti-angiogenic agent for select metastatic cancers.
• Oncology nurses require specialized knowledge to manage bevacizumab therapy and its associated toxicities.
• Optimizing patient outcomes necessitates a comprehensive approach to bevacizumab treatment and side effect management.